Precision Medicine in Inflammatory Bowel Disease.

Area of Science:

• Gastroenterology
• Immunology
• Computational Biology

Background:

• Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is viewed as a spectrum of heterogeneous phenotypes.
• Its etiology involves a complex interplay of genetic predisposition, immune response, environmental triggers, altered intestinal permeability, and gut microbiota dysbiosis.

Purpose of the Study:

• To review the current challenges in IBD management, including treatment efficacy and the need for predictive markers.
• To explore the potential of artificial intelligence (AI) and machine learning (ML) in advancing precision and personalized medicine for IBD patients.

Main Methods:

• Review of current literature on IBD pathogenesis, treatment modalities, and emerging AI/ML applications.
• Analysis of unmet needs in predicting treatment response, disease progression, and severity.

Main Results:

• Current IBD therapies exhibit an unsatisfactory success rate, with a lack of predictive factors for outcomes and response.
• There is a critical need for accurate biomarkers to guide treatment decisions and avoid under- or over-treatment.

Conclusions:

• AI and ML algorithms hold significant promise for improving IBD management by enabling precision and personalized medicine.
• Addressing the challenges associated with AI/ML implementation is crucial for realizing their full potential in IBD care.